跳至主要内容
临床试验/NCT01436838
NCT01436838已完成不适用

Prospective Study of Betaferon in Adherence, Coping and Nurse Support in Patients of Chinese Origin With Multiple Sclerosis

Bayer0 个研究点目标入组 110 人开始时间: 2012年3月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Bayer
入组人数
110
主要终点
Adherence to Betaferon treatment: proportion of patients adhering to Betaferon treatment

研究概览

简要总结

Non-adherence reduces treatment benefit and can bias the assessment of treatment efficacy thereby involving safety risks for the patient and influencing health cost-effectiveness. This observational study will concentrate upon the role of MS nurses in influencing adherence. This study will examine the influence of initial and subsequent periodic nurse interviews which aim to improve adherence to Betaferon® treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Relapsing-remitting multiple scelrosis (RRMS) and secondary progressive multiple sclerosis (SPMS) patients
  • Having Betaferon treatment, including patients who are
  • First time using; or
  • Re-staring; or
  • Switching from other diseases modifying drugs (DMDs)

排除标准

  • Known or newly identified contraindication for administration of Betaferon according to Summary of Product Characteristic (SmPC).

研究组 & 干预措施

Group 1

干预措施: Interferon beta-1b (Betaseron, BAY86-5046) (Drug)

结局指标

主要结局

Adherence to Betaferon treatment: proportion of patients adhering to Betaferon treatment

时间窗: at 6, 12, 18 and 24 months

次要结局

  • Ways of Coping Questionnaire (WCQ)(at 6, 12, 18 and 24 months)
  • Hospital Anxiety and Depression Scale (HAD)(at 6, 12, 18 and 24 months)

研究者

发起方
Bayer
申办方类型
Industry
责任方
Sponsor

相似试验

China Betaferon Adherence, Coping and Nurse Support... | 临床试验